News and Announcements
Dimerix Annual Update 2015; Lists on the ASX & Commences Phase II Clinical Study
- Published December 17, 2015 11:09AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Dimerix Bioscience has made substantial progress in a number of corporate and operational areas in 2015. In July, Dimerix Bioscience was acquired by Sun Biomedical (who subsequently changed its name to Dimerix Limited ASX:DXB). On 17th December, Dimerix announced the appointment of Dr Liz Jazwinska as a non executive director. Dr Jazwinska brings more than 25 years experience in Science and Business with Senior Roles in Industry, Academia and Government in Australia, New Zealand, UK, and Asia Pacific, including 7 years at Johnson and Johnson Research Pty Ltd.
Dimerix’s lead clinical program, a Phase II study in Chronic Kidney Disease, DMX-200, is now recruiting patients with the company aiming to provide interim data in mid 2016. Upon successful results, Dimerix intends to pursue the registration of a product for an orphan indication, and was recently granted Orphan Drug Designation for DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) by the FDA.
ABOUT DIMERIX
Dimerix is an Australian biotech company developing and commercialising novel drug therapies targeted at unmet patient needs, with the lead clinical program targeting chronic kidney disease (CKD).
Dimerix conducts its laboratory operations via contracts with the University of Western Australia and the Harry Perkins Institute of Medical Research, WA. Dimerix is working with established clinical research organisations for its clinical studies.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
